Asset Details
Do you wish to reserve the book?
Hyperoxygenation revitalizes Alzheimer’s disease pathology through the upregulation of neurotrophic factors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Hyperoxygenation revitalizes Alzheimer’s disease pathology through the upregulation of neurotrophic factors
Do you wish to request the book?
Hyperoxygenation revitalizes Alzheimer’s disease pathology through the upregulation of neurotrophic factors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Hyperoxygenation revitalizes Alzheimer’s disease pathology through the upregulation of neurotrophic factors
2019
Overview
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by Aβ‐induced pathology and progressive cognitive decline. The incidence of AD is growing globally, yet a prompt and effective remedy is not available. Aging is the greatest risk factor for AD. Brain aging proceeds with reduced vascularization, which can cause low oxygen (O2) availability. Accordingly, the question may be raised whether O2 availability in the brain affects AD pathology. We found that Tg‐APP/PS1 mice treated with 100% O2 at increased atmospheric pressure in a chamber exhibited markedly reduced Aβ accumulation and hippocampal neuritic atrophy, increased hippocampal neurogenesis, and profoundly improved the cognitive deficits on the multiple behavioral test paradigms. Hyperoxygenation treatment increased the expression of BDNF, NT3, and NT4/5 through the upregulation of MeCP2/p‐CREB activity in HT22 cells in vitro and in the hippocampus of mice. In contrast, siRNA‐mediated inhibition of MeCP2 or TrkB neurotrophin receptors in the hippocampal subregion, which suppresses neurotrophin expression and neurotrophin action, respectively, blocked the therapeutic effects of hyperoxygenation on the cognitive impairments of Tg‐APP/PS1 mice. Our results highlight the importance of the O2‐related mechanisms in AD pathology, which can be revitalized by hyperoxygenation treatment, and the therapeutic potential of hyperoxygenation for AD.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Aging
/ Alzheimer Disease - metabolism
/ Alzheimer Disease - pathology
/ Amyloid beta-Peptides - antagonists & inhibitors
/ Amyloid beta-Peptides - metabolism
/ Animals
/ Atrophy
/ BDNF
/ Brain-derived neurotrophic factor
/ Brain-Derived Neurotrophic Factor - metabolism
/ Cyclic AMP response element-binding protein
/ MeCP2
/ Mice
/ siRNA
